{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:48:52Z","timestamp":1790516932590,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Burden of aspergillosis is reported to be significant from developing countries including those in South Asia. The estimated burden in Pakistan is also high on the background of tuberculosis and chronic lung diseases. There is concern for management of aspergillosis with the emergence of azole resistant\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      species in neighbouring countries in Central and South Asia.\n                    <\/jats:p>\n                    <jats:p>\n                      Hence the aim of this study was to screen significant\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      species isolates at the Microbiology Section of Aga Khan Clinical Laboratories, Pakistan, for triazole resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A descriptive cross-sectional study, conducted at the Aga Khan University Laboratories, Karachi, from September 2016\u2013May 2019. One hundred and fourteen, clinically significant\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      isolates [\n                      <jats:italic>A. fumigatus<\/jats:italic>\n                      (38; 33.3%),\n                      <jats:italic>A. flavus<\/jats:italic>\n                      (64; 56.1%),\n                      <jats:italic>A. niger<\/jats:italic>\n                      (9; 7.9%)\n                      <jats:italic>A. terreus<\/jats:italic>\n                      (3; 2.6%)] were included. The clinical spectrum ranged from invasive aspergillosis (IA) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200925; 21.9%), chronic pulmonary aspergillosis (CPA) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200958; 50.9%), allergic bronchopulmonary aspergillosis (ABPA) (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u20094; 3.5%), severe asthma with fungal sensitization (SAFS) (n\u2009=\u20094; 3.5%), saprophytic tracheobronchial aspergillosis (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200923; 20.2%). Screening for triazole resistance was performed by antifungal agar screening method. The minimum inhibitory concentration (MIC) of 41 representative isolates were tested and interpreted according to the Clinical and Laboratory Standards Institute broth microdilution method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All the isolates were triazole-susceptible on agar screening. MICs of three azole antifungals for 41 tested isolates were found to be \u22641\u2009ml\/L; all isolates tested were categorized as triazole-susceptible, including 4 isolates from patients previously on triazole therapy for more than 2 weeks. The minimum inhibitory concentration required to inhibit the growth of 90% organisms (MIC\n                      <jats:sub>90<\/jats:sub>\n                      ) of itraconazole, voriconazole and posaconazole of the representative\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      isolates was 1\u2009mg\/L, 1\u2009mg\/L and 0.5\u2009mg\/L, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Triazole resistance could not be detected amongst clinical\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      isolates from the South of Pakistan. However, environmental strains remain to be tested for a holistic assessment of the situation. This study will set precedence for future periodic antifungal resistance surveillance in our region on\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      isolates.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-020-00731-8","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:02:55Z","timestamp":1589187775000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Screening for triazole resistance in clinically significant Aspergillus species; report from Pakistan"],"prefix":"10.1186","volume":"9","author":[{"given":"Safia","family":"Moin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9921-4660","authenticated-orcid":false,"given":"Joveria","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kauser","family":"Jabeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Laiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afia","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"issue":"s6","key":"731_CR1","first-page":"49","volume":"20","author":"C. LF.","year":"2014","unstructured":"C. LF. Susceptibility testing in Aspergillus species complex. Clin Microbiol Infect. 2014;20(s6):49\u201353.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"731_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1469-0691.2011.03503.x","volume":"18","author":"HLL Xu","year":"2012","unstructured":"Xu HLL, Huang WJ, Wang LX, Li WF, Yuan WF. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: a case control study from China. Clin Microbiol Infect. 2012;18(4):403\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"731_CR3","volume-title":"Burden of invasive fungal infections in developing countries. MYCOSES","author":"A Chakrabarti","year":"2015","unstructured":"Chakrabarti A. Burden of invasive fungal infections in developing countries. MYCOSES; 2015."},{"key":"731_CR4","doi-asserted-by":"crossref","unstructured":"Jabeen K, Farooqi J, Mirza S, Denning D, Zafar A. Serious fungal infections in Pakistan. Eur J Clin Microbiol Infect Dis. 2017;36(6):949\u201356.","DOI":"10.1007\/s10096-017-2919-6"},{"key":"731_CR5","first-page":"12","volume":"58","author":"SM Immaculata Xess","year":"2004","unstructured":"Immaculata Xess SM, Jain N, jee UB. Prevalence of Aspergillus spp.in clinical samples isoalted in an Indian Tertiary care Hopsital. Ind J Med Sci. 2004;58:12.","journal-title":"Ind J Med Sci"},{"key":"731_CR6","first-page":"S1","volume":"56","author":"NI MI","year":"2018","unstructured":"MI NI, Jabeen K, Farooqi J. Clinical features and outcome of Chronic Pulmonary Aspergillosis: experience from a high tuberculosis burden country. Medical Mycology,ISHAM. 2018;56:S1\u2013S159 2018:PP1.044.","journal-title":"Medical Mycology,ISHAM"},{"issue":"5","key":"731_CR7","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1111\/j.1439-0507.2010.01996.x","volume":"54","author":"MGE Shivaprakash","year":"2011","unstructured":"Shivaprakash MGE, Chakrabarti A, Mouton JW, Meis JF. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses. 2011;54(5):e583\u2013e9.","journal-title":"Mycoses."},{"key":"731_CR8","first-page":"428","volume":"6","author":"CS Anuradha Chowdhary","year":"2015","unstructured":"Anuradha Chowdhary CS, Kathuria S, Hagen F, Meis JF. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol. 2015;6:428.","journal-title":"Front Microbiol"},{"issue":"9","key":"731_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/cid\/cir179","volume":"52","author":"DWPS Denning","year":"2011","unstructured":"Denning DWPS, Lass-Florl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52(9):1123\u20139.","journal-title":"Clin Infect Dis"},{"key":"731_CR10","doi-asserted-by":"crossref","unstructured":"Verweij PECA, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2015;civ885.","DOI":"10.1093\/cid\/civ885"},{"issue":"4","key":"731_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1473-3099(15)70006-X","volume":"15","author":"SBR Schelenz","year":"2015","unstructured":"Schelenz SBR, Barton RC, Cleverley JR, Lucas SB, Kibbler CC, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis. 2015;15(4):461\u201374.","journal-title":"Lancet Infect Dis"},{"key":"731_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13054-014-0722-7","volume":"19","author":"A-MVA Fabio Silvio Taccone","year":"2015","unstructured":"Fabio Silvio Taccone A-MVA, Bulpa P, on behalf of the AspICU Study Investigators, et al. Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Taccone et al Critical Care. 2015;19:7.","journal-title":"Taccone et al Critical Care"},{"key":"731_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1513\/pats.200906-050AL","volume":"7","author":"CAH Radek Dutkiewicz","year":"2010","unstructured":"Radek Dutkiewicz CAH. Aspergillus infections in the critically ill. Proc Am Thorac Soc. 2010;7:204\u20139.","journal-title":"Proc Am Thorac Soc"},{"issue":"Iss. 1","key":"731_CR14","first-page":"56","volume":"186","author":"I Stijn","year":"2012","unstructured":"Stijn I, Blot FST, Van den Abeele A-M, the AspICU Study Investigators, et al. A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients. Am J Respir Crit Care Med. 2012;186(Iss. 1):56\u201364.","journal-title":"Am J Respir Crit Care Med"},{"key":"731_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","volume":"70","author":"DWD Chris Kosmidis","year":"2015","unstructured":"Chris Kosmidis DWD. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015;70:270\u20137. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206291.","journal-title":"Thorax."},{"issue":"3","key":"731_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1086\/525258","volume":"46","author":"WTJ AE","year":"2008","unstructured":"AE WTJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327\u201360.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"731_CR17","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"BWT De Pauw","year":"2008","unstructured":"De Pauw BWT, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer\/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"731_CR18","volume-title":"Atlas of clinical fungi, Centraalbureau voor Schimmelcultures Universitat Rovira i Virgili","author":"GGJ De Hoog","year":"2000","unstructured":"De Hoog GGJ, Gene J, Figueras M. Atlas of clinical fungi, Centraalbureau voor Schimmelcultures Universitat Rovira i Virgili; 2000."},{"key":"731_CR19","volume-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard. CLSI document M38-A2","author":"Clinical, Institute LS","year":"2008","unstructured":"Clinical, Institute LS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi: Approved Standard. CLSI document M38-A2 2008."},{"issue":"11","key":"731_CR20","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1128\/AAC.00692-10","volume":"54","author":"KLME Mortensen","year":"2010","unstructured":"Mortensen KLME, Lass-Fl\u00f6rl C, Rodriguez-Tudela JL, Johansen HK, Arendrup MC. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Int J Antimicrob Agents. 2010;54(11):4545\u20139.","journal-title":"Int J Antimicrob Agents"},{"key":"731_CR21","doi-asserted-by":"crossref","unstructured":"Iqbal N IM, Zubairi A, Jabeen K, Awan S, J. Clinical Manifestations and Outcomes of Pulmonary Aspergillosis ; Experience from Pakistan\". BMJ resp research manuscript ID is bmjresp. 2016;K 2016\u2013000155.R1.","DOI":"10.1136\/bmjresp-2016-000155"},{"key":"731_CR22","doi-asserted-by":"publisher","unstructured":"Iqbal N, Irfan M, Zubairi AB, Jabeen K, Awan S, Khan JA. Clinical manifestations and outcomes of pulmonary aspergillosis: experience from Pakistan. BMJ Open Respir Res. 2016;3(1):e000155. https:\/\/doi.org\/10.1136\/bmjresp-2016-000155.","DOI":"10.1136\/bmjresp-2016-000155"},{"key":"731_CR23","doi-asserted-by":"publisher","unstructured":"Tsitsopoulou A, Posso R, Vale L, Bebb S, Johnson E, White PL. Determination of the Prevalence of Triazole Resistance in Environmental Aspergillus fumigatus Strains Isolated in South Wales, UK. Front Microbiol. 2018;9:1395. https:\/\/doi.org\/10.3389\/fmicb.2018.01395.","DOI":"10.3389\/fmicb.2018.01395"},{"issue":"9","key":"731_CR24","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1128\/AAC.00514-12","volume":"56","author":"KI Masato Tashiro","year":"2012","unstructured":"Masato Tashiro KI. A Katsuji Hirano et al. correlation between Triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy September. 2012;56(9):4870\u20135.","journal-title":"Antimicrobial Agents and Chemotherapy September"},{"key":"731_CR25","first-page":"7","volume":"59","author":"RZ Musang Liu","year":"2015","unstructured":"Musang Liu RZ, Zhang L, et al. Multiple cyp51A-Based Mechanisms Identified in Azole-Resistant Isolates of Aspergillus fumigatus from China. Antimicrob Agents Chemother. 2015;59:7.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Issue 12","key":"731_CR26","doi-asserted-by":"publisher","first-page":"e52871","DOI":"10.1371\/journal.pone.0052871","volume":"7","author":"SK Anuradha Chowdhary","year":"2012","unstructured":"Anuradha Chowdhary SK, Meis JF, et al. Clonal Expansion and Emergence of Environmental Multiple-Triazole-Resistant Aspergillus fumigatus Strains Carrying the TR34\/L98H Mutations in the cyp51A Gene in India. PloS one. 2012;7(Issue 12):e52871.","journal-title":"PloS one"},{"key":"731_CR27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1099\/jmm.0.000255","volume":"65","author":"TS Mojtaba Nabili","year":"2016","unstructured":"Mojtaba Nabili TS, Moazeni M, et al. High prevalence of clinical and environmental triazole-resistant Aspergillus fumigatus in Iran: is it a challenging issue? J Med Microbiol. 2016;65:468\u201375.","journal-title":"J Med Microbiol"},{"key":"731_CR28","first-page":"20150460","volume":"B 371","author":"F Jacques","year":"2016","unstructured":"Jacques F, Meis AC, Johanna L, Rhodes M, Fisher C, Paul E. Verweij. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Phil Trans R Soc. 2016;B 371:20150460.","journal-title":"Phil Trans R Soc"},{"issue":"3","key":"731_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/21501203.2019.1574927","volume":"10","author":"STJS Sonia Kumari Shishodia","year":"2019","unstructured":"Sonia Kumari Shishodia STJS. Resistance mechanism and proteins in Aspergillus species against antifungal agents. Mycology. 2019;10(3):151\u201365.","journal-title":"Mycology"},{"key":"731_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/jof5030055","volume":"5","author":"M Shivaprakash","year":"2019","unstructured":"Shivaprakash M, Rudramurthy RAP, Chakrabarti A, Mouton JW, Meis JF. Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management. J Fungi. 2019;5:55.","journal-title":"J Fungi"},{"issue":"10","key":"731_CR31","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1128\/JCM.00940-09","volume":"47","author":"MAP DJD","year":"2009","unstructured":"DJD MAP, Ghannoum MA, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three Triazoles as determined by the clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol. 2009;47(10):3142\u20136.","journal-title":"J Clin Microbiol"},{"key":"731_CR32","first-page":"82","volume":"8","author":"AI Maria Khan","year":"2018","unstructured":"Maria Khan AI, Zaman G, Gardezi A, Lalani FK. Pattern of antifungal susceptibility in pathogenic molds by microdilution method at a tertiary care hospital. Ann Med Health Sci Res. 2018;8:82\u20136.","journal-title":"Ann Med Health Sci Res"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00731-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-020-00731-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00731-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T19:13:38Z","timestamp":1620674018000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00731-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00731-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.17755\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.17755\/v2","asserted-by":"object"}]},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical exemption was obtained from the institutional ethics review committee.Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}